VENUSREM Stock View

Venus Remedies Ltd
stock-view-header

₹ 338.65

icon 36.30 | 10.72
Market Cap ₹( Cr.)
4,526.73
Proj. P/E (x)
Proj. P/BV (x)
0.85
Proj. ROE (%)
Proj EV / EBITDA (x)
--
Proj. Revenue ( Cr.)
6,111.00

Stock View

STRONG BUY

Last Updated On.
25-Feb-2024
 

The average score for Venus Remedies Ltd stands at 10 against 6, three months back.

Venus Remedies Ltd is a research-based pharmaceutical company. The Company is a global injectable manufacturer, possessing a wide product basket catering to therapeutic segments of anti-infective specially in antimicrobial resistance (AMR), oncology, skin and wound care and pain management. The Company operates in the Pharmaceutical Formulation segment. It manufactures products catering to the critical care and super specialty segments. The Company's product portfolio includes formulations such as injectables, tablets, and topical preparations. The Company offers solutions in the domains of antimicrobial resistance (AMR), oncology, skin & wound care, neurology, anticoagulants, pain management, herbal portfolio and disinfectants. Its focus therapy areas include medicine, surgery, neuro and orthopedics. The Company’s brands include Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, Ventaful and Nervolize. It has three manufacturing facilities.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.


Technical Data

50 DMA(₹)
387.59
100 DMA(₹)
350.61
200 DMA(₹)
294.58
52 Weeks Range
151.15     429.60

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required